Literature DB >> 11025709

Whole mounted radical prostatectomy specimens do not increase detection of adverse pathological features.

B K Hollenbeck1, N Bassily, J T Wei, J E Montie, S Hayasaka, J M Taylor, M A Rubin.   

Abstract

PURPOSE: The optimal method to process radical prostatectomy specimens to maximize the detection of adverse pathological features is unclear and accurate staging is critical. We compare the ability of whole mounted sections to detect these features compared to partially submitted radical prostatectomy specimens.
MATERIALS AND METHODS: A total of 93 consecutive radical prostatectomy specimens were processed as whole mounts. Tissue sections were analyzed and the pathological outcomes measured included Gleason score, surgical margin status, and presence or absence of extraprostatic tumor extension and/or seminal vesicle invasion. The pathological outcomes of the preceding cohort were compared to those of a similar cohort consisting of 554 men whose radical prostatectomy specimens were processed as partially submitted glands.
RESULTS: A multivariate logistic regression analysis was performed to determine the effect of the method of tissue processing on the pathological outcomes. When considered alone or adjusted for various preoperative patient characteristics (prostate specific antigen, biopsy Gleason score and clinical stage), there were no significant differences in the ability of whole mounted specimens to detect the various outcomes compared to partially submitted specimens (all p >0.4).
CONCLUSIONS: Whole mounted sampling of the radical prostatectomy specimen does not improve detection of adverse pathological features.

Entities:  

Mesh:

Year:  2000        PMID: 11025709

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique.

Authors:  S G Jhavar; C Fisher; A Jackson; S A Reinsberg; N Dennis; A Falconer; D Dearnaley; S E Edwards; S M Edwards; M O Leach; C Cummings; T Christmas; A Thompson; C Woodhouse; S Sandhu; C S Cooper; R A Eeles
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

2.  Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.

Authors:  Raquel Esgueva; Kyung Park; Robert Kim; Naoki Kitabayashi; Christopher E Barbieri; Philip J Dorsey; Cyril Abraham; Samprit Banerjee; Robert A Leung; Ashutosh K Tewari; Stéphane Terry; Maria M Shevchuk; David S Rickman; Mark A Rubin
Journal:  Diagn Mol Pathol       Date:  2012-06

3.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.

Authors:  Marc Barry; Sven Perner; Francesca Demichelis; Mark A Rubin
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

4.  Dysregulation of the annexin family protein family is associated with prostate cancer progression.

Authors:  Wei Xin; Daniel R Rhodes; Collette Ingold; Arul M Chinnaiyan; Mark A Rubin
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

5.  Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.

Authors:  Chandan Kumar-Sinha; Rajal B Shah; Bharathi Laxman; Scott A Tomlins; Jason Harwood; Werner Schmitz; Ernst Conzelmann; Martin G Sanda; John T Wei; Mark A Rubin; Arul M Chinnaiyan
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

Review 6.  Tumor focality in prostate cancer: implications for focal therapy.

Authors:  Markos Karavitakis; Hashim U Ahmed; Paul D Abel; Steven Hazell; Mathias H Winkler
Journal:  Nat Rev Clin Oncol       Date:  2010-11-23       Impact factor: 66.675

7.  The role of pathology correlation approach in prostate cancer index lesion detection and quantitative analysis with multiparametric MRI.

Authors:  Andriy Fedorov; Tobias Penzkofer; Michelle S Hirsch; Trevor A Flood; Mark G Vangel; Paul Masry; Clare M Tempany; Robert V Mulkern; Fiona M Fennessy
Journal:  Acad Radiol       Date:  2015-02-13       Impact factor: 3.173

8.  Partial versus complete prostatectomy specimen sampling: prospective non-inferiority study for pT3a tumours and surgical margin involvement.

Authors:  Eelco R P Collette; Michael A den Bakker; Sjoerd O Klaver; André N Vis; Mike Kliffen
Journal:  BMJ Open       Date:  2019-04-11       Impact factor: 2.692

9.  HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.

Authors:  Steven C Smith; Nallasivam Palanisamy; Kimberly A Zuhlke; Anna M Johnson; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju; Kathleen A Cooney; Scott A Tomlins
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.